Impact of Tocilizumab on COVID-19 Patients Requiring Vasopressor Support

Background on COVID-19

COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. The symptoms of the virus can vary widely, ranging from asymptomatic cases to severe conditions such as acute respiratory distress syndrome (ARDS), which remains a leading cause of mortality among affected individuals.

Cytokine Storms and Their Consequences

Pro-inflammatory cytokines are molecules released by immune cells that promote inflammation. An overproduction of these cytokines can lead to severe complications, including low blood pressure, thrombosis, pulmonary edema, and multi-organ failure, collectively known as a cytokine storm. ARDS, frequently associated with cytokine storms, has been responsible for numerous fatalities in COVID-19 patients, with evidence suggesting that these storms may correlate with poor outcomes.

Tocilizumab: A Potential Treatment

Tocilizumab is an immunosuppressive medication already approved for treating cytokine release syndrome (CRS). Researchers have explored its potential benefits for COVID-19 patients exhibiting high levels of pro-inflammatory cytokines.

Study Overview

Published in EClinicalMedicine, a recent study evaluated 51 COVID-19 patients who were admitted between March 13 and April 19, 2020, and were experiencing hypoxia. Among these patients, 29 received tocilizumab, while 23 did not. All participants were given a loading dose of 400mg Hydroxychloroquine twice daily, followed by a maintenance dose of 200mg twice daily for five days. Additionally, 500mg Azithromycin was administered for five days unless contraindicated. Patients with hypoxia, lung infiltrates on chest X-ray, elevated inflammatory biomarkers, and no contraindications were eligible for a single dose of tocilizumab.

Study Results

The study’s findings indicated that patients treated with tocilizumab experienced a higher rate of improvement in oxygen support. Notably, these patients required less time on vasopressor support and invasive mechanical ventilation. The average duration for those needing vasopressor support and invasive mechanical ventilation was three days shorter for the tocilizumab group compared to those who did not receive the drug. Furthermore, patients on invasive mechanical ventilation showed an average improvement five days sooner when treated with tocilizumab.

Hospital Stay Length and Interpretation of Results

While the length of hospital stay was longer for patients receiving tocilizumab, this was attributed to a higher proportion needing intensive care admission. As this study is a small, retrospective analysis, the results should be interpreted with caution. The findings suggest that tocilizumab may offer benefits for patients with severe COVID-19, particularly in terms of quicker recovery and reduced reliance on vasopressors and mechanical ventilation. However, further clinical trials are essential to validate these results.

Conclusion

The study presents promising insights into the use of tocilizumab for severe COVID-19 cases, indicating potential improvements in recovery times. Ongoing research will be crucial to confirm its efficacy in treating this challenging condition.

References

Kewan, T., Covut, F., Al–Jaghbeer, M., Rose, L., Gopalakrishna, K., and Akbik, B., 2020. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. EClinicalMedicine, p.100418.

Written by Helen Massy, BSc.